NCT04958967 2025-03-14Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion MutationAllist Pharmaceuticals, Inc.Phase 1 Withdrawn
NCT05693090 2023-03-06Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung CancerKura Oncology, Inc.Phase 1 Withdrawn